How does GILD's Q4 2024 EPS performance compare to previous quarters?

Gilead Sciences' Q4 2024 EPS of $1.42 demonstrates a significant improvement compared to the previous quarter, Q3 2024, where the EPS was $1.01. This trend is also reflected in the EPS estimates for the full year 2024, which were decreased by analysts after Q3 2024, with the FY2024 EPS estimate for Gilead Sciences, Inc. standing at $4.10 per share, down from the prior estimate of $7.19. Despite this, the Q4 2024 EPS exceeded expectations, with the estimated EPS being $1.16, indicating a robust financial performance. The non-GAAP EPS for Q4 2024 was $1.90, which also surpassed the estimated EPS, reflecting strong product sales and lower costs.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|GILD|GILD.O|Gilead Sciences|2024 Q1|-517.4999999999999|-3.34|185|
|GILD|GILD.O|Gilead Sciences|2024 Q2|55.421686746987966|1.29|185|
|GILD|GILD.O|Gilead Sciences|2024 Q3|-42.19653179190752|1|185|
|GILD|GILD.O|Gilead Sciences|2024 Q4|24.561403508771935|1.42|185|